Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 7/20 | 0.76 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763787 | 0.87 | NQO2 (0.78) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL17108183 | 0.86 | NQO2 (1.00) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL7200117 | 0.84 | NQO2 (0.72) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL6764471 | 0.83 | NQO2 (0.74) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL1311849 | 0.82 | MTNR1A (1.00) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL31543690 | 0.81 | MTNR1A (0.72) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL26989714 | 0.79 | MTNR1A (0.80) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL29766820 | 0.77 | MTNR1A (1.00) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL4655625 | 0.77 | MTNR1A (1.00) | NQO2MTNR1AMTNR1BCYP1A2CYP3A4 | |
| SCHEMBL9667084 | 0.76 | MTNR1A (0.65) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | PINTOR JESUS J (ES) | 2004-10-07 | — | — | US | claimed |
| US-6730707-B2 | SUCH AS 5-(METHOXYCARBONYLAMINO)-N-ACETYLTRYPTAMINE; TREATING OCULAR HYPERTENSION, VARIOUS FORMS OF GLAUCOMA | INSPIRE PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| EP-1307191-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | Inspire Pharmaceuticals, Inc. (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | claimed |
| WO-2002009702-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | INSPIRE PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | PINTOR JESUS J (ES) | 2004-10-07 | — | — | US | disclosed |
| US-6730707-B2 | SUCH AS 5-(METHOXYCARBONYLAMINO)-N-ACETYLTRYPTAMINE; TREATING OCULAR HYPERTENSION, VARIOUS FORMS OF GLAUCOMA | INSPIRE PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | MTNR1A, MTNR1B, MC5R | NQO2 984/4885MTNR1A 1/4885MTNR1B 2/4885 |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | MTNR1A, MTNR1B, MC5R | NQO2 619/4885MTNR1A 1/4885MTNR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.